Yes, kratom shows up on urine tests, but only when the test is built to look for it. Standard workplace panels skip it entirely, so detection depends on buying a kratom-specific dip card, strip, or multi-panel cup with mitragynine listed as an analyte. Rapid kits give a presumptive result in minutes; a positive still needs lab confirmation by LC-MS/MS before anyone treats it as definitive.
TL;DR:
- Kratom detection in urine tests requires a specific kit that tests for mitragynine, as standard panels do not include it, and positive results need lab confirmation.
- Rapid test kits like dip cards and strips provide quick presumptive results in minutes but cannot replace confirmatory LC-MS/MS analysis for legal or occupational decisions.
- Sensitivity cutoff levels vary, with some retail dip cards detecting down to 250 ng/mL, although most are around 300 ng/mL, emphasizing the importance of validated, validated testing protocols.
- Detection windows depend on dose and usage frequency, with half-lives estimated from 12 to over 60 hours, causing variability in how long kratom remains detectable.
- For reliable results, vendors should clearly publish cutoff levels, validation status, and confirmatory workflows, avoiding any kits that lack transparent performance data or validated cutoffs.
Most buyers land in one of three categories: someone screening themselves at home, a clinic that needs a reliable single-analyte option, or a workplace program running a full panel. A few products stand out for each.
Confirmatory testing is not built into any rapid kit. A presumptive positive from a dip card, strip, or cup has to be sent to a lab running LC-MS/MS if the result needs to hold up for an employer, a court, or a treatment program. Most of these products are sold through medical supply retailers and general online marketplaces, with availability shifting by season and vendor stock.
Twelve kratom urine tests circulate in the retail and clinical supply market, and they split cleanly by format and intended buyer.
None of these publish a confirmatory LC-MS/MS cutoff themselves. That step always happens at a separate lab, regardless of which rapid kit flags the initial positive.
Picking a kit comes down to five questions you can run through before you buy.
Ask any vendor directly about their published cutoff value, whether the product has been validated against a CLIA-certified lab, and what their confirmatory workflow looks like if a result needs to be contested. A vendor that cannot answer those questions plainly is not one to trust with a result that matters.
Pro Tip: Treat any kit that advertises a “guaranteed” result or skips a published cutoff as a red flag, not a shortcut.
A missing cutoff, a vague sensitivity claim, or no stated path to confirmatory testing are the clearest signs a kit is built for casual reassurance rather than a result you can stand behind.
Rapid dip cards and cups work on immunoassay chemistry: an antibody reacts to mitragynine or a related compound and produces a visual line. That reaction is fast and cheap, but it is calibrated to a threshold, not to the exact molecule. Peer-reviewed analysis notes that presumptive immunoassays can produce false negatives when they are not calibrated for mitragynine’s metabolites, and that confirmatory testing resolves those gaps by separating the compound from its diastereomers.
Confirmatory labs run LC-MS/MS, which separates mitragynine from closely related diastereomers like speciociliatine and speciogynine instead of lumping them together the way a rapid card does.

Mitragynine’s terminal half-life has been estimated at roughly 12 to more than 60 hours depending on dose and individual metabolism, which is why detection windows vary so widely between occasional and frequent users. Dose, frequency of use, and assay sensitivity all shift how long a positive stays detectable.
Dip cards and strips are sold as single units or in boxes of 25 and 100, mostly through medical supply retailers and general online marketplaces; cup-style multi-panel tests follow the same pack logic but at a higher per-unit price because of the added analytes.
A rapid kit is a screening tool, not a verdict. Federal workplace panels still do not list kratom biomarkers as routine analytes, so anyone relying on a drug test for a legal or occupational decision needs a validated lab method and supervised collection, not a dip card bought online. Treat a positive from any of these kits as a starting point that belongs in a confirmatory lab, never as the final word.
— MIchael
Membership with NursingScience.org gives you access to deeper guides on collection procedures and test interpretation, including our breakdown of supervised drug test protocols. 
If you are weighing a kratom screen against a legal or workplace requirement, read that guide first, then explore membership options built for nursing professionals who want evidence-based resources on testing practice.

A kratom-specific immunoassay can misfire if it is not properly calibrated for mitragynine’s metabolites, producing an inaccurate screen in either direction. Confirmatory LC-MS/MS testing resolves this by separating mitragynine from its diastereomers before reporting a result.
A standard 12-panel urine test screens for common drug classes like opiates, amphetamines, and cannabinoids, and it does not include kratom unless the product specifically lists a kratom panel. The Identify Health 12 Panel Kratom Drug Test Cup is built with that panel included, which is not the case for a generic 12-panel device.
Federal workplace testing guidelines do not currently authorize kratom biomarkers as part of standard urine panels, so routine drug court testing typically will not catch it unless a specific request is made. When kratom detection matters for a legal proceeding, the testing program has to order a validated biomarker test with a confirmatory lab workflow.
Detection time depends heavily on dose and frequency, since mitragynine’s half-life estimates range from about 12 to more than 60 hours across individuals. Someone using kratom occasionally will clear it faster than a regular, higher-dose user.